Autoinflammatory diseases: The hereditary periodic fever syndromes

Acta Biomedica de l'Ateneo Parmense

Volumn 75, Issue 2, 2004, Pages

  Fietta, Pieranna ^a  

^a Parma Hospital   (Italy)

Author keywords

Familial Mediterranean fever; Hereditary periodic fever syndromes; Human autoinflammatory diseases; Hyperimmunoglobulinemia D and periodic fever syndrome; Tumor necrosis factor receptor superfamily 1A associated periodic syndrome

Indexed keywords

COLCHICINE; CORTICOSTEROID; ETANERCEPT; GENE PRODUCT; MARENOSTRIN; MEVALONATE KINASE; MEVALONIC ACID; PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ARTHRITIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL FEATURE; ERYTHEMA; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENE; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN AUTOINFLAMMATORY DISORDER; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATORY DISEASE; MEFV GENE; MVK GENE; ONSET AGE; PAIN; RASH; REVIEW; TNFRSF1A GENE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ACUTE-PHASE REACTION; ADOLESCENT; ADULT; AMYLOIDOSIS; ANTIGENS, CD; CHILD; CYTOSKELETAL PROTEINS; ETHNIC GROUPS; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENES, DOMINANT; GENES, RECESSIVE; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN D; INFLAMMATION; NEUROCUTANEOUS SYNDROMES; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; STOMATITIS, APHTHOUS; URTICARIA;

EID: 19444373105     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Galon J, Aksentijevich I, McDermott F, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12: 479-86.
2. Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15: 61-9.
3. Drenth JPH, van der Meer JWM. Hereditary periodic fever. N Engl J Med 2001; 345: 1748-57.
4. Delpech M, Grateau G. Genetically determined recurrent fevers. Curr Opin Immunol 2001; 13: 539-42.
5. Gumucio DL, Diaz A, Schaner P, et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 2002; 20 (Suppl. 26): S45-S53.
6. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS). Emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81: 349-68.
7. Orbach H, Ben-Chetrit E. Familial Mediterranean fever. A review and update. Minerva Med 2001; 92: 421-30.
8. Rozenbaum M, Rosner I. The clinical features of familial Mediterranean fever of elderly onset. Clin Exp Rheumatol 1994; 12: 347-8.
9. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996; 26: 612-27.
10. Langevitz P, Livneh A, Zemer D, Shemer Y, Pras M. Sero-negative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997; 27: 67-72.
11. Mehkoglu M, Ozdogan H, Korkmaz C, et al. A survey of phenotype II in familial Mediterranean fever. Ann Rheum Dis 2000; 59: 910-3.
12. Pras E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosen L, Dean M. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med 1992; 326: 1509-13.
13. Dodé C, Pécheux C, Cazeneuve C, et al. Mutations in the MEFVgene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 2000; 92: 241-6.
14. Gershoni-Baruch R, Brik R, Shinavi M, Livneh A. The different contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002; 10: 145-9.
15. Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis. Phenotype-genotype correlation, treatment and prognosis. J Nephrol 2003; 16: 431-4.
16. Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001; 102: 272-6.
17. Ben-Chetrit E, Lerer I, Malamud E, Domingo C, Abeliovich D. The E148Q mutation in the MEFVgene: is it a disease-causing mutation or a sequence variant? Hum Mutat 2000; 15: 385-6.
18. Dewalle M, Domingo C, Rozenbaum M, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever. Eur J Hum Genet 1998; 6: 95-7.
19. Touitou I, Picot MC, Domingo C, et al. The MICA region determines the first modifier locus in familial Mediterranean fever. Arthritis Rheum 2001; 44: 163-9.
20. Cazeneuve C, Ajrapctyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000; 67: 1136-43.
21. Aldea A, Campistol JM, Arostegui JI, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet 2004; 124A: 67-73.
22. Centola M, Wood G, Frucht DM, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95: 3223-31.
23. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathways. Proc Natl Acad Sci USA 2003; 100: 13501-6.
24. Aypar E, Ozen S, Okur H, Kutluk T, Besbas N, Bakkaloglu A. Th1 polarization in familial Mediterranean fever. J Rheumatol 2003; 30: 2011-3.
25. Notarnicola C, Didelot MN, Seguret F, Demaille J, Touitou I. Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun 2002; 3: 43-5.
26. Kiraz S, Ertenli I, Ozturk MA, et al. Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis. J Rheumatol 2003; 30: 313-5.
27. Centola M, Aksentijevich I, Kastner DL. The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Hum Mol Genet 1998; 7: 1581-8.
28. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85.
29. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002; 61: 79-81.
30. Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 1999; 26: 890-7.
31. Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha levels in familial Mediterranean fever patients. Clin Rheumatol 2003; 22: 99-101.
32. Medlej-Hashim M, Petit I, Adib S, et al. Familial Mediterranean fever: association with elevated IgD plasma levels with specific MEFV mutations. Eur J Hum Genet 2001; 9: 849-54.
33. Ben-Chetrit E, Levy M. Colchicine update - 1998. Semin Arthritis Rheum 1998; 28: 48-59.
34. Tunca M, Ben-Chetrit E. Familial Mediterranean fever in 2003. Pathogenesis and management. Clin Exp Rheumatol 2003; 21 (Suppl. 30): S49-S52.
35. Frenkel J, Houten SM, Waterham HR, et al. Mevalonate kinase deficiency and Dutch type periodic fever. Clin Exp Rheumatol 2000; 18: 525-32.
36. Livneh A, Drenth JP, Klasen IS, et al. Familial Mediterranean fever and hyperimmunoglobulinemia D syndrome: two diseases with distinct clinical, serologic and genetic features. J Rheumatol 1997; 24: 1558-63.
37. Drenth JP, van Deuren M, van der Velde Visser S, Schalkwijk CG, van der Meer JW. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995; 85: 3586-93.
38. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22: 178-81.
39. Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002; 46: 2794-803.
40. Drenth JP, Powell RJ, Brown NS, van der Meer JW. Interferon-gamma and urine neopterin in attacks of hyperimmunoglobulinemia D and periodic fever syndrome. Eur J Clin Invest 1995; 25: 683-6.
41. Cuisset L, Drenth JP, Simon A, et al. Molecular analysis of MVK mutations and enzymatic activity in hyper IgD and periodic fever syndrome. Eur J Hum Genet 2001; 9: 260-6.
42. Simon A, Mariman EC, van der Meer JWM, Drenth JP. Major mutation of the hyper-IgD and periodic fever syndrome originates from one common ancestor - truly Dutch type periodic fever? Clin Exp Rheumatol 2002; 20 (Suppl. 26): S-74.
43. Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993; 91: 915-21.
44. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet 1999; 22: 175-7.
45. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003; 60: 1118-34.
46. Drenth JP, Vonk AG, Simon A, Powell R, van der Meer JW. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double blind, placebo controlled trial. J Pharmacol Exp Ther 2001; 298: 1221-6.
47. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48: 2645-51.
48. Hentgen V, Granel B, Dodé C, Cuisset L, Delpech M, Grateau G. Tumor necrosis factor receptor superfamily 1A-associated periodic syndrome (TRAPS). Rev Méd Interne 2003; 24: 781-5.
49. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
50. McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997; 72: 806-17.
51. Dodé C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J Nephrol 2003; 16: 435-7.
52. Sarrauste de Mentière C, Terrière S, Pugnère D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003; 31: 282-5.
53. Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype study and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 301-14.
54. Aganna E, Hammond L, Hawkins PN, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48: 2632-44.
55. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003; 42: 235-9.